Spots Global Cancer Trial Database for refractory tumor
Every month we try and update this database with for refractory tumor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Neoantigen Derived DCs as Cancer Treatment | NCT05767684 | Refractory Tumo... Solid Tumor | Dendritic Cell ... Lenvatinib Nivolumab | 20 Years - | National Health Research Institutes, Taiwan | |
| Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors | NCT00028405 | Liver Metastasi... Pelvic Cancer Head and Neck C... Sarcoma Rectal Cancer Breast Cancer Colorectal Canc... Mouth Cancer | LS 11(Taporfin ... Lumaflex Light ... | 18 Years - | Light Sciences LLC | |
| Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance | NCT06202599 | Bone Sarcoma Soft Tissue Sar... Refractory Tumo... | Fruquintinib | - | Peking University People's Hospital | |
| Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors | NCT04900519 | Solid Tumor Relapsed Solid ... Refractory Tumo... | STI-6643 | 18 Years - | Sorrento Therapeutics, Inc. | |
| A Study of DCR-STAT3 in Adults With Solid Tumors | NCT06098651 | Solid Tumor, Ad... Refractory Tumo... | DCR-STAT3 | 18 Years - | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | |
| Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors | NCT04809012 | Solid Tumor Refractory Tumo... Relapsed Solid ... | STI-3031 | 18 Years - | Sorrento Therapeutics, Inc. | |
| Denosumab: A Potential Treatment Option for Aneurysmal Bone Cysts | NCT03415477 | Bone Cyst Aneur... Pathological Fr... Recurrent Disea... Refractory Tumo... | Denosumab (Xgev... | 12 Years - 65 Years | Peking University People's Hospital | |
| Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers | NCT05099549 | Squamous Cell C... Carcinoma, Non-... Colorectal Neop... Advanced Solid ... Refractory Tumo... Metastatic Tumo... | AFM24 SNK01 | 18 Years - | NKGen Biotech, Inc. | |
| A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors | NCT02564198 | Pediatric Solid... Refractory Tumo... Recurrent Tumor CNS Malignancie... | Ramucirumab | 12 Months - 21 Years | Eli Lilly and Company | |
| Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors | NCT00028405 | Liver Metastasi... Pelvic Cancer Head and Neck C... Sarcoma Rectal Cancer Breast Cancer Colorectal Canc... Mouth Cancer | LS 11(Taporfin ... Lumaflex Light ... | 18 Years - | Light Sciences LLC | |
| Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers | NCT05099549 | Squamous Cell C... Carcinoma, Non-... Colorectal Neop... Advanced Solid ... Refractory Tumo... Metastatic Tumo... | AFM24 SNK01 | 18 Years - | NKGen Biotech, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
